India’s antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.
Summit Therapeutics is about to start pivotal tests of a novel antibiotic discovered by UK scientists to treat a sometimes deadly bowel infection, but Britons could be the last patients to get it after Britain leaves the EU.
Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.
As AstraZeneca continues to move its operations to new headquarters in Cambridge, England, the company quietly pushed back its timeline for a late-stage lung cancer trial.
Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.
Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.
The U.S. Food and Drug Administration posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. The products are marketed and sold without FDA approval, most commonly on websites and social media platforms.
Less than 10 days after OncoMed Pharmaceuticals announced its mid-stage combination lung cancer treatment failed to meet endpoints, the company slashed half its workforce in an effort to focus its finances on three clinical-stage programs.
AstraZeneca’s move to the English university city of Cambridge will cost more and take longer than initially expected, following increased expenditure on new technology and equipment.
Germany-based Fresenius Kabi, part of Fresenius SE & Co. KGaA, slapped down $4.3 billion to acquire Illinois-based Akorn Inc. and a larger toehold in the United States.